Passage Bio to Engage at Global Investment Conference
Passage Bio, Inc. (NASDAQ: PASG), known for its innovative approach in genetic medicines, will participate in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event is set to take place from September 8-10 in New York City and presents an excellent opportunity for the company to showcase its advancements in treating neurodegenerative diseases.
Company Insights and Key Presentations
The presentation will be led by Will Chou, M.D., the president and CEO of Passage Bio. His discussion will provide insights into the company's mission and ongoing projects aimed at enhancing the lives of patients afflicted by challenging neurodegenerative conditions.
Management Engagement with Investors
During the conference, Passage Bio management will also conduct one-on-one meetings with investors, allowing for deeper engagement and discussions about the company's future strategies and innovations. These sessions are crucial for building relationships and ensuring transparency with stakeholders.
Webcast Availability
For those unable to attend in person, the presentation will be accessible through a video webcast. Registered attendees can access it via the conference platform starting from early September, and it will also be made available on Passage Bio’s investor relations website, ensuring that all interested parties can stay informed about the company’s latest developments.
Passage Bio’s Commitment to Innovation
Passage Bio is unwavering in its commitment to developing pioneering therapies that can significantly impact how neurodegenerative diseases are treated. The company strives to improve not only patient outcomes but also the quality of life for patients and their families.
Focus on Neurodegenerative Disorders
Currently, Passage Bio's lead product candidate, PBFT02, is a potential one-time therapy that targets frontotemporal dementia and similar conditions. By focusing on elevating progranulin levels, this therapy aims to restore lysosomal function, a crucial component in mitigating the progression of neurodegenerative diseases.
Inspiring Hope for Patients and Families
Passage Bio’s work reflects a deep understanding of the needs of patients battling neurodegenerative disorders. The organization not only focuses on groundbreaking treatments but also on building a robust support system for patients and their families. Their mission is to foster hope and provide comprehensive care through innovative solutions and compassionate outreach.
Engage with Passage Bio for More Information
As Passage Bio prepares for the conference, those interested in learning more about its advancements and commitment to tackling neurodegenerative diseases can visit the official website. Potential investors can find detailed information that highlights the strategic direction and future prospects of the company.
Contact Information for Further Inquiries
Investors seeking more information can reach out to Stuart Henderson at Passage Bio via email. Moreover, media inquiries can be directed to Mike Beyer at Sam Brown Inc., where dedicated professionals are ready to assist with any questions and provide further assistance.
Frequently Asked Questions
What is the focus of Passage Bio?
Passage Bio focuses on developing genetic medicines for neurodegenerative diseases, aiming to improve patient outcomes.
Who will be presenting at the investment conference?
Will Chou, M.D., the president and CEO, will present on behalf of Passage Bio.
How can I watch the presentation if I cannot attend?
A video webcast will be available on the company’s website for registered attendees and those interested.
What is PBFT02?
PBFT02 is the lead product candidate aimed at treating frontotemporal dementia by restoring critical cellular functions.
How can I get in touch with Passage Bio for more information?
Contact information for investor relations and media inquiries is provided on the company’s website for anyone seeking further details.
